Heartseed raises USD 14m for stem-cell therapy development
With proceeds from a Series D round, a phase I/II trial can be completed with a stem-cell therapy candidate against heart failure to which Novo Nordisk retains global rights outside Japan.
by albert rønning-andersson, translated by daniel pedersen
Japanese biotech company Heartseed has raised JYP 2bn (USD 14.3m) in a Series D financing round with new and existing participation, according to a company press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
